Oncolytics Biotech

Oncolytics Biotech Inc. is a biopharmaceutical firm in its development phase, concentrating its efforts on discovering and creating novel pharmaceutical agents to combat cancer. Its primary therapeutic candidate is pelareorep, an immunotherapeutic drug delivered intravenously, designed to target and treat both solid tumors and various blood-related cancers. The company has established strategic co-development agreements with major pharmaceutical companies, Merck KGaA and Pfizer Inc., as well as with PrECOG LLC. These collaborations are focused on advancing pelareorep for use in conjunction with paclitaxel and avelumab (a human anti-PD-L1 antibody). This specific combination therapy is being developed to address hormone receptor-positive, human epidermal growth factor 2-negative metastatic breast cancer. Oncolytics Biotech Inc. was founded in 1998 and is based in Calgary, Canada.